Status:
COMPLETED
A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension
Lead Sponsor:
Allergan
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
This safety study will evaluate bimatoprost 0.01% and 0.03% in patients with glaucoma or ocular hypertension (OHT).
Eligibility Criteria
Inclusion
- Diagnosis of glaucoma or ocular hypertension
Exclusion
- Active ocular disease other than glaucoma or ocular hypertension
- Require chronic use of ocular medications other than the study medication during the study (intermittent use of artificial tear solution will be permitted)
Key Trial Info
Start Date :
July 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
466 Patients enrolled
Trial Details
Trial ID
NCT01830140
Start Date
July 1 2013
End Date
May 1 2014
Last Update
May 6 2015
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Artesia, California, United States
2
El Paso, Texas, United States